Liam Dunne, MSD Biotech Site Lead, speaks to Danielle Barron about how the Dublin site is leveraging the latest technologies, from real-time process monitoring to the latest upstream techniques, helping to ensure reliability and quality of global supply.
Credit: MSD
Bringing a therapeutic to market is a long and complex process. ‘From bench to bedside’ is a well-known aphorism that merely hints at the arduous journey drug treatments must undergo from their position as a candidate molecule or soon to be explored pathway, to becoming a tablet, injection, or infusion administered to patients worldwide.
This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.
Key learning points:
Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
Learn about ITM’s implementation journey and considerations when evaluating the technology
Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).
Don’t miss your chance to learn from experts in the industry –Register for FREE
Can’t attend live? No worries – register to receive the recording post-event.
The scientific rigour of development and the various regulatory hurdles involved mark most of that journey. But scaling up production and ensuring global supply of sensitive biological pharmaceuticals is a remarkable process that embodies Industry 4.0 – the rapid technological advancement that is characterising the fourth industrial revolution – and the very latest in advanced manufacturing technologies.
Extensive upstream and downstream development is needed to achieve robustness of the commercial manufacturing process, make the drug product at scale and deliver on consistent product quality”
The product lifecycle from discovery of druggable targets to commercialisation of the product takes several years. Extensive upstream and downstream development is needed to achieve robustness of the commercial manufacturing process, make the drug product at scale and deliver on consistent product quality. Every stage is imbued with a need for speed given the unmet needs patients face. In a modern manufacturing facility, sophisticated biologics analytical R&D are responsible for this, determining the unique ‘thumbprint’ of the product and ensuring the preservation of the product quality profile from the first deliveries made to the last.
MSD Dublin Biotech is a digitally-enabled biologics drug substance facility, which plays a pivotal role in the manufacture of MSD’s biologics‑based medicines. It is capable of supplying these potentially life-changing biologics to more than 650,000 cancer patients annually around the world. How does it do this? Liam Dunne, MSD Biotech Site Lead, explains that the site operates at the forefront of science and technology with 15,000L-scale, repeatable, robust manufacturing processes to produce highly sensitive monoclonal antibodies (mAbs).
Manufacturing biologics-based medicines is a complex but fascinating endeavour. At MSD Biotech, the process begins with single cloned cells, which are then grown and multiplied in aqueous-based systems from flasks, through single-use bioreactors and then through stainless steel bioreactors, each capable of holding 15,000 litres. After six weeks of cell mitosis (division and duplication), a therapeutic mAb is produced. The product is purified, formulated and then sterile‑filled into vials and syringes for administration to patients.
Understandably, this process is tightly controlled and highly standardised. Steps to optimise the process can always be taken, Dunne notes, such as making careful changes in upstream or downstream, but the quality of the product must always remain the same.
Upstream and downstream innovation
To this end, MSD Biotech Dublin uses innovative processing technology and digital innovation in executing, controlling, monitoring and optimising all aspects of operations. These innovative technologies include highly automated, fully digitalised process analytics technologies (PAT), as well as automated and robotic testing technologies to confirm product quality. “Machine learning, as well as augmented reality and virtual reality techniques, are used to deliver ongoing scheduling, maintenance, operations and process improvement,” says Dunne.
The complex and intricate processes involved in upstream and downstream manufacturing are highly refined, he notes. Upstream manufacturing involves the inoculation, incubation and expansion of cells in bioreactors to promote growth of the protein of interest. The process, which starts with a single vial, ultimately produces 15,000L of cell culture fluid within a production reactor. This is harvested through a centrifuge and filtered into the first downstream production vessel. Downstream processing then involves capturing the protein of interest and completing a series of purification steps across eight unit operations to produce the final formulated product, which is then sent for forward processing.
Cutting-edge technologies ensure this process is optimised to be as streamlined and efficient as possible, says Dunne. One such technology being employed is alternating tangential flow filtration (ATF) perfusion. He outlines this novel technology that is often used in the biopharmaceutical industry and now being implemented for biologics processes. “It allows for continuous addition of fresh media and removal of spent media, ensuring a continuous fresh nutrient supply to bioreactor cells and the ongoing removal of cell waste and metabolites,” he explains. “This significantly improves growth conditions, allowing for a 10-fold increase in viable cell density, meaning more protein production, and also reduces the time spent culturing cells in the bioreactor, meaning more batches can be delivered.”
Credit: MSD Biotech Dublin facility and team
Creating the cell line factories in the large‑scale bioreactors for manufacture is a long and complicated process, with significant time dedicated to cell-line development (8-12 months) within the product development cycle. This is followed by multiple-week lead times for inoculum expansion and seed expansion before production, which also takes weeks. As part of the upstream process, a reliable platform supports speed to the clinic, with a strong reliance on platform processes and high throughput tools for experimentation. The downstream process ensures cell removal, virus safety, and impurity removal. “There are 22 tests required to characterise and release a typical therapeutic protein but advances in analytics mean these can now be moved to the process floor through the incorporation of PAT,” says Dunne. “This ensures that product quality is maintained throughout the product development lifecycle.”
Four key principles
The development of MSD Biotech Dublin was launched with the vision of ensuring a consistent and unrestricted supply of innovative immuno‑oncology products to patients around the world. To develop and maintain this world‑leading facility, the MSD Biotech Dublin team has focused on four key principles to ensure an innovative and efficiency-driven approach: Reliability, Lean Manufacturing, Digitalisation and a High Performing Culture.
Dunne offers some key examples of each:
Reliability: ‘Right first time’ successful on‑time process performance qualification (PPQ) lots started less than three years after facility construction commenced – with no quality or contamination issues
Lean manufacturing: The Merck Production System (MPS) programme continually challenges MSD Biotech Dublin to eliminate waste and encourages all employees to be effective problem solvers and ensure the patient is in mind when driving business improvement
Digitalisation: With real-time process monitoring and a dedicated manufacturing, science and technology laboratory onsite, MSD Biotech Dublin was successfully able to improve yields by 25 percent per batch
High Performing Culture: Employees are the driving force behind everything they do. Having successfully recruited 380 employees since 2018, their aim is to manage retention levels of 92 – 95 percent, providing the necessary operational stability while also creating room for personal growth and development opportunities in the organisation. Since transitioning from start-up phase to full operational capability they consistently achieve retention rates of 93 – 94 percent.
optimisation of the process and investment in new technologies has enabled the site to further enhance manufacturing capabilities to triple output annually, meaning more patients can avail of potentially life-changing medicines – and the facility is now targeting to serve 650,000 patients annually by 2026″
Adhering to these principles has allowed the facility to achieve an industry leading ramp-up rate and economy of scale. “Indeed, optimisation of the process and investment in new technologies has enabled the site to further enhance manufacturing capabilities to triple output annually, meaning more patients can avail of potentially life-changing medicines – and the facility is now targeting to serve 650,000 patients annually by 2026,” says Dunne. “By leveraging the latest innovation in lean, agile and flexible models, the state-of-the-art site is primed to meet the always-evolving healthcare needs of populations worldwide”.
Liam Dunne joined MSD 27 years ago, first in the Ballydine Site in Ireland, where he held various roles in operations and technical support. He then moved to other MSD locations, notably in Singapore as technical operations head and the US to lead Global Pharmaceutical Commercialisation across drug substances, products and packaging. Since 2021, Liam Dunne is the site head of MSD Biotech in Dublin. He graduated from University College Dublin with a degree in chemical engineering and completed an MSc in pharmacy at the University of Manchester.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.